Gain Therapeutics, Inc. (GANX) News
Track canonical SquawkNews coverage tagged to GANX, Gain Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
GANX gain Therapeutics CEO Gene mack issues letter to shareholders and provides operational update Gain Therapeutics - to commence phase 2 s
GANX gain Therapeutics CEO Gene mack issues letter to shareholders and provides operational update Gain Therapeutics - to commence phase 2 study of rexaceract in Q3 2026
EQUITY | Jul 16, 2026, 11:00 AM UTC
L
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ: GANX ) with a Buy and maintains $8 price target.
EQUITY | Jul 01, 2026, 11:46 AM UTC
H
Gain Therapeutics Obtains FDA Clearance Of IND To Advance GT-02287 Into Phase 2 Clinical Development for Parkinson’s Disease; IND Authorizat
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA’s decision follows positive Phase 1 results for GT-02287 in both healthy volunteers and people
EARNINGS | Jun 29, 2026, 08:08 PM UTC